New botulinum neurotoxin constructs for treatment of chronic pain
- PMID: 37041008
- PMCID: PMC10098373
- DOI: 10.26508/lsa.202201631
New botulinum neurotoxin constructs for treatment of chronic pain
Abstract
Chronic pain affects one in five people across human societies, with few therapeutic options available. Botulinum neurotoxin (BoNT) can provide long-lasting pain relief by inhibiting local release of neuropeptides and neurotransmitters, but its highly paralytic nature has limited its analgesic potential. Recent advances in protein engineering have raised the possibility of synthesising non-paralysing botulinum molecules for translation to pain sufferers. However, the synthesis of these molecules, via several synthetic steps, has been challenging. Here, we describe a simple platform for safe production of botulinum molecules for treating nerve injury-induced pain. We produced two versions of isopeptide-bonded BoNT from separate botulinum parts using an isopeptide bonding system. Although both molecules cleaved their natural substrate, SNAP25, in sensory neurons, the structurally elongated iBoNT did not cause motor deficit in rats. We show that the non-paralytic elongated iBoNT targets specific cutaneous nerve fibres and provides sustained pain relief in a rat nerve injury model. Our results demonstrate that novel botulinum molecules can be produced in a simple and safe manner and be useful for treating neuropathic pain.
© 2023 Leese et al.
Conflict of interest statement
B Davletov has received consultancy fees from Allergan and was a PI on a separate research project sponsored by Allergan. C Leese and C Christmas were previously working on a separate research project sponsored by Allergan. The patent application describing isopeptide-bonded BoNTs was filed by the University of Sheffield (PCT/GB2020/052991). B Davletov is a founder of the Neuresta company. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising from this submission.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_Fig1.gif)
![Figure S1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_FigS1.gif)
![Figure S2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_FigS2.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_Fig2.gif)
![Figure S3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_FigS3.gif)
![Figure S4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_FigS4.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_Fig3.gif)
![Figure S5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_FigS5.gif)
![Figure S6.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_FigS6.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_Fig4.gif)
![Figure S7.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10098373/bin/LSA-2022-01631_FigS7.gif)
Similar articles
-
Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain.Eur J Pharmacol. 2016 Nov 15;791:377-388. doi: 10.1016/j.ejphar.2016.09.019. Epub 2016 Sep 9. Eur J Pharmacol. 2016. PMID: 27619001
-
Intrathecal administration of botulinum toxin type a antagonizes neuropathic pain by countering increased vesicular nucleotide transporter expression in the spinal cord of chronic constriction injury of the sciatic nerve rats.Neuropeptides. 2023 Aug;100:102346. doi: 10.1016/j.npep.2023.102346. Epub 2023 May 8. Neuropeptides. 2023. PMID: 37178626
-
Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia.J Headache Pain. 2017 Dec;18(1):38. doi: 10.1186/s10194-017-0744-z. Epub 2017 Mar 21. J Headache Pain. 2017. PMID: 28324318 Free PMC article. Review.
-
Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A.Pain. 2013 Nov;154(11):2547-2553. doi: 10.1016/j.pain.2013.07.041. Epub 2013 Aug 8. Pain. 2013. PMID: 23933181 Free PMC article.
-
Botulinum Toxin Type A-A Modulator of Spinal Neuron-Glia Interactions under Neuropathic Pain Conditions.Toxins (Basel). 2018 Apr 2;10(4):145. doi: 10.3390/toxins10040145. Toxins (Basel). 2018. PMID: 29614835 Free PMC article. Review.
Cited by
-
Recent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications.Toxins (Basel). 2024 Apr 3;16(4):175. doi: 10.3390/toxins16040175. Toxins (Basel). 2024. PMID: 38668600 Free PMC article. Review.
-
Effectiveness of Botulinum Toxin in the Treatment of Neuropathic Pain: A Literature Review.Cureus. 2023 Oct 11;15(10):e46848. doi: 10.7759/cureus.46848. eCollection 2023 Oct. Cureus. 2023. PMID: 37954779 Free PMC article. Review.
-
Therapeutic Applications of Botulinum Neurotoxins in Veterinary Medicine.Vet Sci. 2023 Jul 13;10(7):460. doi: 10.3390/vetsci10070460. Vet Sci. 2023. PMID: 37505863 Free PMC article. Review.
References
-
- Andreou AP, Leese C, Greco R, Demartini C, Corrie E, Simsek D, Zanaboni A, Koroleva K, Lloyd JO, Lambru G, et al. (2021) Double-binding botulinum molecule with reduced muscle paralysis: Evaluation in in vitro and in vivo models of migraine. Neurotherapeutics 18: 556–568. 10.1007/s13311-020-00967-7 - DOI - PMC - PubMed
-
- Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, Raicher I, Uceyler N, Sommer C, Bouhassira D (2016) Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo-controlled trial. Lancet Neurol 15: 555–565. 10.1016/s1474-4422(16)00017-x - DOI - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Medical